CytRx publishes results from Arimoclomol Phase 2 trial for sIBM
Category: #health  By Saipriya Iyer  Date: 2020-02-13
  • sharesocial_share_icon
  • Twitter
  • Facebook
  • LinkedIn

CytRx publishes results from Arimoclomol Phase 2 trial for sIBM

CytRx Corporation, a biopharmaceutical firm that specializes principally in neurodegenerative and oncology diseases, recently announced its data from Orphazyme double-blinded Phase 2 study of arimoclomol for the treatment of sIBM (Sporadic Inclusion Body Myositis).

Reportedly, the study was a 24-patient randomized pilot (with 8 patients on placebo and 16 on arimoclomol) where almost 83% of patients receiving treatment from arimoclomol were stabilized whereas 25% managed to be stabilized in placebo.

Orphazyme trial is expected to be completed by the end of 2020, with interim analysis coming in the first half of 2020. Moreover, the results from this study are slated to be revealed by the first half of 2021, with regulatory submission being submitted by the second half of 2021.

Speaking on the move, Eric Curtis, President and Chief Operating Officer, CytRx, said that the company is with the findings of Phase 2 clinical study treating sIBM with arimoclomol. Moreover, it is projected that there are nearly 40,000 patients in Europe and the USA who go through this debilitating disease and presently there are no effective therapies for this massive population of sIBM patients.

Incidentally, CytRx has also announced that Orphazyme A/S licensed arimoclomol has completed a major new capital raise of around $110 million for expansion. Orphazyme claims that the funding will support the finalization of arimoclomol's clinical advancements in sIBM and help prepare regulatory filings in Europe and possibly in the U.S.

The investment also offers noteworthy cash for Orphazyme to further arimoclomol towards commercialization in NPC. Orphazyme also aims at using the proceeds to cover the completion of clinical development of arimoclomol in ALS.

Reports claim that CytRx is eligible to receive over $120 million in future milestones, along with royalties, from the company’s arimoclomol licensing deal. If received, the investment would secure a minimum of $250 million in net operating losses.

Source Credit: https://cytrxcorporation.gcs-web.com/news-releases/news-release-details/cytrx-corporation-highlights-recently-published-data-its?field_nir_news_date_value%5Bmin%5D=2017&items_per_page=10#views-exposed-form-widget-news-widget-news-ul



About Author

Saipriya Iyer

Email: [email protected]   linkdin twitter

Saipriya Iyer

Saipriya Iyer develops content for Market Size Forecasters, Algosonline, and myriad other platforms. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her bel...

More News By Saipriya Iyer

 Tabletop Tape Dispensers  market valuation to surge at healthy CAGR through 2026

Tabletop Tape Dispensers market valuation to surge at healthy CAGR through 2026

By Saipriya Iyer

A comprehensive research study on Tabletop Tape Dispensers market added by Market Study Report provides insights into the market size and growth trends of this industry over the forecast timeline. The study evaluates key aspects of Tabletop Tape D...

APAC, Europe, America region to generate massive revenues for General Well-Being Dietary Supplements market by 2026

APAC, Europe, America region to generate massive revenues for General Well-Being Dietary Supplements market by 2026

By Saipriya Iyer

MarketStudyReport.com presents latest report on global General Well-Being Dietary Supplements Market, which evaluates the growth trends of the industry through historical study and estimates future prospects based on comprehensive research. The re...

Eugenia Jambolana Extract Market to Increase Exponentially During 2027

Eugenia Jambolana Extract Market to Increase Exponentially During 2027

By Saipriya Iyer

The report Eugenia Jambolana Extract market provides high-quality information regarding the major market trends, product types and their application scope, competitive landscape, and impact of COVID-19 outbreak.

.

Request a...